SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor is seeing intense community focus driven by its upcoming first halving event and momentum from Grayscales recently filed Form 10 for a spot ETF. Investors are heavily discussing TAO's scarcity model, its role as a decentralized AI infrastructure leader, and the high-yield staking opportunities across its expanding subnet ecosystem.

The Stellar network is an open source, distributed, and community owned network used to facilitate cross-asset transfers of value. Stellar aims to help facilitate cross-asset transfer of value at a fraction of a penny while aiming to be an open financial system that gives people of all income levels access to low-cost financial services. Stellar can handle exchanges between fiat-based currencies and between cryptocurrencies. Stellar.org, the organization that supports Stellar, is centralized like XRP and meant to handle cross platform transactions and micro transactions like XRP. However, unlike Ripple, Stellar.org is non-profit and their platform itself is open source and decentralized.   Stellar was founded by Jed McCaleb in 2014. Jed McCaleb is also the founder of Mt. Gox and co-founder of Ripple, launched the network system Stellar with former lawyer Joyce Kim. Stellar is also a payment technology that aims to connect financial institutions and drastically reduce the cost and time required for cross-border transfers. In fact, both payment networks used the same protocol initially.  Distributed Exchange Through the use of its intermediary currency Lumens (XLM), a user can send any currency that they own to anyone else in a different currency.  For instance, if Joe wanted to send USD to Mary using her EUR, an offer is submitted to the distributed exchange selling USD for EUR. This submitted offer forms is known as an order book. The network will use the order book to find the best exchange rate for the transaction in-order to minimize the fee paid by a user.  This multi-currency transaction is possible because of "Anchors". Anchors are trusted entities that hold people’s deposits and can issue credit. In essence, Anchors serves as the bridge between different currencies and the Stellar network.  Lumens (XLM) Lumens are the native asset (digital currency) that exist on the Stellar network that helps to facilitate multi-currency transactions and prevent spams. For multi-currency transactions, XLM is the digital intermediary that allows for such a transaction to occur at a low cost.  In-order to prevent DoS attacks (aka spams) that would inevitably occur on the Stellar network, a small fee of 0.00001 XLM is associated with every transaction that occurs on the network. This fee is small enough so it does not significantly affect the cost of transaction, but large enough so it dissuades bad actors from spamming the network.   Prior to Protocol 12, Stellar had a built-in inflation mechanism conceived to allow account holders to collectively direct inflation-generated lumens toward projects built on Stellar.  As the network evolved and grew, it became increasingly clear that inflation wasn’t working as intended — account holders either didn’t set their inflation destination or joined inflation pools to claim the inflation themselves, and the operational costs associated with inflation payments continued to rise — and so a protocol change to disable inflation was proposed, implemented, voted on by validators, and ultimately adopted as part of a network upgrade.  The inflation operation is now deprecated. https://developers.stellar.org/docs/glossary/inflation/

Stellar Lumens

Stellar Lumens is trending as investors weigh the impact of institutional developments, including its integration into global payment rails and the recent announcement of futures contracts on the CME Group. The community remains deeply polarized, with some members highlighting its utility in real-world asset tokenization, while others express frustration over stagnant price action and persistent market volatility.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is generating buzz as investors speculate on a potential rebound for the NFT sector, with community members highlighting its low market capitalization and limited circulating supply as catalysts for volatility. Traders are actively debating whether this low-cap asset is positioned for a significant breakout or further decline, frequently citing the need for increased exchange listings and volume to sustain momentum.

Dogelon Mars

Dogelon Mars continues to spark intense debate within the crypto community, with many retail holders debating whether it remains a viable OG meme coin or a long-term 'pump and dump' project. While some investors urge patience and point to potential market-wide altcoin cycles, others express frustration over stagnant performance and the lack of utility compared to newer meme tokens.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as investors monitor the company's progress toward sustained positive cash flow alongside high-stakes legal proceedings in the Supreme Court regarding generic patent infringement. Community sentiment remains split between optimism regarding the potential for a strategic buyout or turnaround following corporate restructuring and frustration over the stock's prolonged volatility and stagnant valuation.

The Last Play is Crypto’s 401k.  RETIRE is more than a coin; it’s The Last Play. We are a community dedicated to breaking free from the grind and building true generational wealth. With RETIRE, our mission is simple yet profound: to provide a pathway to retire yourself and secure financial freedom for your bloodline. While others chase hype and trends, we’re focused on creating a legacy that lasts beyond the typical cycle. RETIRE is about making the one move that matters, with a vision for long-term value, freedom, and impact. This isn’t just a meme —it’s a purpose-driven commitment to building a legacy.

The Last Play

RETIRE is trending as the community rallies around a "tokenized retirement" narrative, emphasizing consistent dollar-cost averaging to achieve financial independence. Supporters are actively promoting the token as a disruptive alternative to traditional retirement systems, viewing recent price volatility as a strong accumulation opportunity for long-term growth.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is trending as investors actively debate its role as a key supplier for the next-generation Co-Packaged Optics (CPO) market, particularly concerning its collaboration with TSMC's COUPE platform for major AI chipmakers. While the stock faces ongoing community skepticism due to historical management performance and sluggish legacy revenue, the potential for a breakthrough in AI data center infrastructure has kept sentiment focused on upcoming mass production timelines and potential long-term growth.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is drawing heavy community interest as investors weigh its pivot to front-line AML treatment against the ongoing REGAL Phase 3 trial, which remains a key focus for potential trial halts or buyout speculation. While some investors argue that the stock is currently overhyped and risky due to a narrow margin for error in clinical results, many remain heavily invested, debating the timing of trial events and the broader implications of a successful drug rollout.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing increased volatility and community chatter as investors speculate on the upcoming Goliath mainnet launch and look for signs of institutional accumulation. While some traders express frustration over historical price manipulation and lack of transparency, others are focused on potential breakout patterns and strategic positioning ahead of network milestones.

Fidelity Wise Origin Bitcoin Fund - Fidelity Wise Origin Bitcoin Fund Beneficial Interest

Fidelity Wise Origin Bitcoin Fund

Fidelity Wise Origin Bitcoin Fund is trending as investors actively discuss its role in broader institutional accumulation strategies and potential upside ahead of expected market volatility. Community sentiment remains heavily focused on the fund as a key vehicle for Bitcoin exposure, with users debating the merits of ETF holding versus self-custody while tracking institutional inflows.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corvus Pharmaceuticals (NASDAQ:CRVS) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen lowered Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday...

Corvus Pharmaceuticals (NASDAQ:CRVS) Given Outperform Rating at Oppenheimer

Oppenheimer reiterated an "outperform" rating and set a $33.00 price target (up from $32.00) on shares of Corvus Pharmaceuticals in a report on Friday...

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 6.5% After Earnings Miss

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 6.5% After Earnings Miss...

Corvus Pharmaceuticals Q4 Earnings Call Highlights

Corvus Pharmaceuticals (NASDAQ:CRVS) outlined expanding clinical plans for its selective ITK inhibitor soquelitinib while reporting higher research and development spending for 2025, reflecting a...

Corvus Pharmaceuticals (NASDAQ:CRVS) Issues Earnings Results, Misses Expectations By $0.01 EPS

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Recommendation of "Moderate Buy" by Brokerages

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven analysts that are presently covering the stock, MarketBeat Ratings...

Corvus Pharmaceuticals (CRVS) Projected to Post Quarterly Earnings on Thursday

Corvus Pharmaceuticals (NASDAQ:CRVS) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 12. (View Earnings Report at...

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 9.4% - Here's Why

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 9.4% - Here's What Happened...

Corvus Pharmaceuticals Highlights Soquelitinib Pipeline, Eyes Phase II Atopic Dermatitis Trial in 2026

Corvus Pharmaceuticals (NASDAQ:CRVS) provided an update on its pipeline at Oppenheimer's Annual Healthcare Conference, with Chief Business Officer Jeff Arcara focusing primarily on soquelitinib, the...

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 7.6% - Time to Sell?

Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Down 7.6% - Time to Sell...

$CRVS Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.15 up 16.67% YoY
• Corvus Pharmaceuticals expects its existing cash, cash equivalents, and marketable securities, including proceeds from its January 2026 financing, to fund operations into the second quarter of 2028.

Stocktwits

Corvus Pharmaceuticals Inc

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of -$0.15 up 16.67% YoY
• Corvus Pharmaceuticals expects its existing cash, cash equivalents, and marketable securities, including proceeds from its January 2026 financing, to fund operations into the second quarter of 2028.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Current Price	$15.32
Prev Close	$16.01
Open	$15.75
Dividend Yield	0.00%
50-Day Moving Average	$16.23
Beta	1.42
Avg. Volume	1.44M
PE Ratio	-28.64

52-Week High	$26.95
52-Week Low	$2.54
Market Capitalization	$1.28B
EPS (Annual)	-$0.5372
Price to Book	15.94
Revenue Per Employee	$0.00

CRVS
Corvus Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRVS News

CRVSCorvus Pharmaceuticals Inc